發(fā)布時(shí)間：2018-05-03 06:29

  本文選題：給藥方式 + 權(quán)利要求��； 參考：《中國(guó)新藥雜志》2016年15期

【摘要】：本文結(jié)合實(shí)際案例,探討了"給藥方式"是否對(duì)化合物的制藥用途產(chǎn)生限定作用這一當(dāng)前專利審查實(shí)踐中存在的爭(zhēng)議問題。認(rèn)為對(duì)于僅涉及藥物使用方法的特征,如果這些特征與制藥方法之間不存在直接關(guān)系,則對(duì)權(quán)利要求所請(qǐng)求保護(hù)的制藥方法不具有限定作用。物質(zhì)的醫(yī)藥用途權(quán)利要求中,給藥方式只是醫(yī)生針對(duì)患者選擇服用特定藥物的行為,與所制備的藥物產(chǎn)品中活性成分的含量之間沒有直接關(guān)系,其不能在制藥過程中予以完全體現(xiàn),因此,僅僅體現(xiàn)在用藥過程中的"給藥方式"不能使該用途具有新穎性。
[Abstract]:Combining with practical cases, this paper discusses whether the drug administration mode has a limited effect on the pharmaceutical use of compounds, which is a controversial issue in the current patent review practice. It is considered that if there is no direct relationship between these characteristics and pharmaceutical methods for which only drug use methods are involved, there is no limitation on the pharmaceutical methods claimed for protection. In claims for pharmaceutical uses of substances, medication is administered only in a manner that the doctor chooses to take a specific drug for the patient, and there is no direct relationship with the content of the active ingredient in the drug product that is prepared. It can not be fully embodied in the pharmaceutical process, therefore, only reflected in the drug use of the "way" can not make the use of novelty.
【作者單位】： 國(guó)家知識(shí)產(chǎn)權(quán)局專利局專利審查協(xié)作天津中心;
【分類號(hào)】：R95
，

本文編號(hào)：1837399